Abstract:Acinetobacter baumannii is an opportunistic pathogen with ability to cause serious infection such as bacteremia, ventilator associated pneumonia, and wound infections. As strains of A. baumannii are resistant to almost all clinically used antibiotics and with the emergence of carbapenems resistant phenotypes warrants the search for novel antibiotics. Considering this, herein, a series of computer aided drug designing approach was utilized to search novel chemical scaffolds that bind stronger to MurE ligase enzyme of A. baumannii, which is involved peptidoglycan synthesis. The work identified LAS_22461675, LAS_34000090 and LAS_51177972 compounds as promising binding molecules with MurE enzyme having binding energy score of -10.5 kcal/mol, -9.3 kcal/mol and -8.6 kcal/mol, respectively. The compounds were found to achieve docked inside the MurE substrate binding pocket and established close distance chemical interactions. The interaction energies were dominated by van der Waals and less contributions were seen from hydrogen bonding energy. The dynamic simulation assay predicted the complexes stable with no major global and local changes noticed. The docked stability was also validated by MM/PBSA and MM/GBSA binding free energy methods. The net MM/GBSA binding free energy of LAS_22461675 complex, LAS_34000090 complex and LAS_51177972 complex is -26.25 kcal/mol, -27.23 kcal/mol and -29.64 kcal/mol, respectively. Similarly in case of MM-PBSA, the net energy value was in following order; LAS_22461675 complex (-27.67 kcal/mol), LAS_34000090 complex (-29.94 kcal/mol) and LAS_51177972 complex (-27.32 kcal/mol). The AMBER entropy and WaterSwap methods also confirmed stable complexes formation. Further, molecular features of the compounds were determined that predicted compounds to have good druglike properties and pharmacokinetic favorable. The study concluded the compounds to good candidates to be tested by in vivo and in vitro experimental assays.Communicated by Ramaswamy H. Sarma.

Identification Through Structure-Based Methods of a Bacterial NAD(+)-dependent DNA Ligase Inhibitor That Avoids Known Resistance Mutations.

Identification through structure-based methods of a bacterial NAD(+)-dependent DNA ligase inhibitor that avoids known resistance mutations(vol 24, pg 360, 2014)

Novel Bacterial NAD + -Dependent DNA Ligase Inhibitors with Broad-Spectrum Activity and Antibacterial Efficacy in Vivo

Structure guided understanding of NAD+ recognition in bacterial DNA ligases.

Identification of promising anti-DNA gyrase antibacterial compounds using de novo design, molecular docking and molecular dynamics studies

Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents.

In silico evaluation of usnic acid derivatives to discover potential antibacterial drugs against DNA gyrase B and DNA topoisomerase IV

Unveiling MurE ligase potential inhibitors for treating multi-drug resistant Acinetobacter baumannii

Novel and Structurally Diversified Bacterial DNA Gyrase Inhibitors Discovered through a Fluorescence-Based High-Throughput Screening Assay

Identification of a 2‐aminobenzimidazole scaffold that potentiates gram‐positive selective antibiotics against gram‐negative bacteria

Computational identification of natural product inhibitors against EGFR double mutant (T790M/L858R) by integrating ADMET, machine learning, molecular docking and a dynamics approach

Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.

Mutant anaplastic lymphoma kinase inhibitor identification by integrated in silico approaches

Identification of small molecules that are synthetically lethal upon knockout of the RNA ligase Rlig1 in human cells

Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme

Identification and Characterization of an Allosteric Inhibitory Site on Dihydropteroate Synthase

Structure-activity Relationships OF N-methylthiolated Beta-Lactam Antibiotics with C3 Substitutions and Their Selective Induction of Apoptosis in Human Cancer Cells.

Strategic Design of Lysine-Targeted Irreversible Covalent NDM-1 Inhibitors

Discovery of a potential lead compound for treating leprosy with dapsone resistance mutation in M. leprae folP1

Development of Fragment-Based Inhibitors of the Bacterial Deacetylase LpxC with Low Nanomolar Activity

Fragment-Based Discovery of Novel MUS81 Inhibitors